smh-top biotechs.

POH gets a geurnsey, one of Bioshares favourites.

As you would expect, being the next big bio to break out with its Blockbuster OXYPATCH producing stunning results in trials.

And INSULIN PATCH gets mentioned.



PHOSPHAGENICS (POH, 19¢)

This is one of Blake's favourite stocks. Phosphagenics is also one for those squeamish about needles because it's just moved to phase III trials for a skin patch that will deliver insulin and other medications. It has $27 million in its kitty that will pay for the trials.

It also has a cosmetics line, Elixia, based on its TPM technology that, apparently, makes the anti-ageing skin cream work faster. Bring that on, too.

Bell Potter likes it because of its "shorter lead time to market and low cost of clinical development" and values it at 40¢ a share, more than double its current price.


http://www.smh.com.au/money/patient-route-to-healthy-profits-20120225-1tulf.html